Time for their flu shot? Help protect against pneumococcal pneumonia at the same time

Vaccination rates against pneumococcal pneumonia are sub-optimal despite a vaccine – PNEUMOVAX® 23 (Pneumococcal vaccine, polyvalent) – being funded on the National Immunisation Program (NIP) for patients ≥65 years.4

Opportunistically vaccinating with PNEUMOVAX® 23 at the same time as their annual flu shot in adults 65+ years can help your practice close the gap in vaccination rates and boost protection against pneumococcal pneumonia.

Download the Australian recommendations for pneumococcal vaccination in adults and availability under the NIP.

DOWNLOAD NOW

ASSESS

  • Assess all patients for their risk of pneumococcal pneumonia.
  • Identify patients who are eligible for pneumococcal pneumonia vaccination and have missed out.

INFORM

  • Educate patients on pneumonia risks – see the resources in the Community Immunity toolbox.
  • Patients can self-assess at www.pneumorisk.com.au.

MAKE A DIFFERENCE

  • Your recommendation can drive the uptake of adult vaccinations in your practice.6

PNEUMOVAX® 23 is also PBS listed for vulnerable adults7

Patients aged 18-64 years with immunocompromising conditions that increase susceptibility to pneumococcal infections e.g.

  • Asplenia
  • Diabetes
  • Chronic heart, lung, liver disease
  • HIV/AIDS
  • Tobacco smokers

Download the NHMRC recommendations for adult vaccination against pneumococcal pneumonia from Community Immunity

DOWNLOAD NOW

PBS Information: Pneumovax® 23 is listed on the National Immunisation Program (NIP) and the Pharmaceutical Benefits Scheme (PBS). Refer to the NIP and PBS Schedule.

Before prescribing, please review Product Information available here. Further information is available on request from Seqirus.

1. Australian Government, Department of Health. Health Topics: Pneumococcal Disease. Available at: https://beta.health.gov.au/health-topics/pneumococcal-disease [accessed February 2019]. 2. Menzies R et al. Vaccine myopia: adult vaccination also needs attention. Med J Aust. 2017;206(6):2.e1. 3. Earle K et al. Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective. Pneumonia (Nathan). 2016;8:9. 4. Australian Government, Department of Health. National Immunisation Program: Older Australians. Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/older-australians [Accessed January 2019]. 5. Health Stats NSW Influenza and pneumococcal disease immunisation by age, trend. Available at: http://www.healthstats.nsw.gov.au/Indicator/com_flupneumoimmu_age/com_flupneumoimmu_age_snap [Accessed January 2019]. 6. Family Medicine Research Centre. University of Sydney. SAND abstract No. 223 from the BEACH program. Sydney: FMRC University of Sydney, 2014. Available at: http://sydney.edu.au/medicine/fmrc/publications/sand-abstracts/223-pneumococcal_vaccination.pdf [accessed February 2019] 7. Australian Government, Department of Health. Pharmaceutical Benefits Scheme. Available at: http://www.pbs.gov.au/medicine/item/10210J-1903E [accessed February 2019].


Proudly sponsored by:

Seqirus (Australia) Pty Ltd. 63 Poplar Road, Parkville, VIC 3052. ABN 66 120 398 067. Medical Information: 1800 42 865. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. Date of preparation: July 2018. SEQ/PNEU/0518/0116b

Cart

Cart

Item removed. Undo